期刊
EXPERIMENTAL AND THERAPEUTIC MEDICINE
卷 22, 期 1, 页码 -出版社
SPANDIDOS PUBL LTD
DOI: 10.3892/etm.2021.10107
关键词
interleukin-15; cancer immunotherapy; combination immunotherapy; natural killer cells; T cells
资金
- Ministry of Research and Innovation in Romania, under Program 1-Improvement of the National System of Research and Development, Subprogram 1.2-Institutional Excellence-Projects of Excellence Funding in RDI [7PFE/16.10.2018, 19.29.02.03, 337PED/2020]
IL-15 is a promising candidate for cancer immunotherapy, as it enhances antitumor responses by promoting the activation of T cells, B cells, and NK cells.
The immune system is dysfunctional in cancer, and therapeutic approaches designated to restore immunity and increase long-term overall survival are desirable. The role of immunotherapy is to trigger the immune system to recognize and destroy tumor cells. Interleukin-15 (IL-15) is a member of the common gamma-chain (gamma c) cytokines that promote the differentiation and expansion of T cells, B cells and natural killer (NK) cells, leading to enhanced antitumor responses. This suggests that IL-15 is a promising candidate for anticancer therapy. Renewed interest in cancer immunotherapy has led to an increased number of preclinical studies and clinical trials that have investigated the reliability and potency of IL-15-based agents, not only as single therapy, but also in combination with others. This review provides a description of these studies which show the advantages and disadvantages of IL-15 as an immunotherapeutic agent. We present here the role of IL-15 and pharmacologically improved IL-15 superagonists as a single treatment or in combination with other therapeutic agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据